2.89 USD
▼-0.08-2.69%
盘后 2.94 +1.73%
2026-09-15
市值
$200.85M
市盈率
—
EPS
-1.19
股息率
—
52 周区间
1.31 – 7.80
成交量
567.27K
Beta
1.97
目标价
10.19
52W 低 1.3152W 高 7.80
价格走势
公司简介
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Bo...